BENDAMUSTINE : A NEW OPTION FOR RELAPSED/ REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Cerchione, C. [1 ]
Madonna, E. [1 ]
Marano, L. [1 ]
Pugliese, N. [1 ]
Avilia, S. [1 ]
Cerciello, G. [1 ]
Pane, F. [1 ]
Catalano, L. [1 ]
机构：
[1] AOU Federico II, Hematol, Naples, Italy
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B1538
引用
收藏
页码：612 / 612
页数：1
相关论文
共 50 条
  • [21] Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
    Cerchione, Claudio
    Nappi, Davide
    Di Perna, Maria
    Zacheo, Irene
    Pareto, Anna Emanuele
    Picardi, Marco
    Catalano, Lucio
    Pane, Fabrizio
    CASE REPORTS IN HEMATOLOGY, 2016, 2016
  • [22] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    I-Jun Lau
    Dean Smith
    Robin Aitchison
    Norbert Blesing
    Pamela Roberts
    Andrew Peniket
    Kwee Yong
    Neil Rabin
    Karthik Ramasamy
    Annals of Hematology, 2015, 94 : 643 - 649
  • [23] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    Lau, I-Jun
    Smith, Dean
    Aitchison, Robin
    Blesing, Norbert
    Roberts, Pamela
    Peniket, Andrew
    Yong, Kwee
    Rabin, Neil
    Ramasamy, Karthik
    ANNALS OF HEMATOLOGY, 2015, 94 (04) : 643 - 649
  • [24] NEW TREATMENTS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Terpos, Evangelos
    LEUKEMIA RESEARCH, 2016, 49 : S14 - S15
  • [25] New hope for relapsed and refractory multiple myeloma
    Leleu, Xavier
    LANCET ONCOLOGY, 2013, 14 (11): : 1028 - 1029
  • [26] The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma
    Andreu-Vieyra, Claudia V.
    Berenson, James R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (06) : 197 - 210
  • [27] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [28] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    Blood Cancer Journal, 9
  • [29] BENDAMUSTINE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2015, 100 : 743 - 744
  • [30] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
12345